This is of particular importance as mutations in DNMT3a are associated with poor outcomes in myelodysplastic syndrome and acute myeloid leukemia patients [7, 8], indicating a potential risk of tumorigenesis if DNMT3a is targeted by epigenetic drugs. Here, DNMT3A is linked to myelodysplastic syndrome.